Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Roles and regulations of APE1 in ATR signaling

Award Number: R01CA291546
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2025
PERIOD OF PERFORMANCE END DATE: 02/28/2030

Group Awards By:

View Award Description

Roles and regulations of APE1 in ATR signaling - Project Summary/Abstract Genome of all cells are constantly exposed to endogenous insults such as reactive oxygen species and environmental toxins, leading to different types of DNA damage such as Apurinic/apyrimidinic (AP) sites, single-strand breaks (SSBs), and single-strand DNA (ssDNA) gaps. Although a good progress has been made on how a global ATR-mediated checkpoint signaling is triggered by DNA damage, it remains elusive how the ATR signaling is activated by ssDNA gaps derived from DNA damage and replication stress, and in the nucleoli where the RNA polymerase I-mediated rRNA transcription and ribosome assembly take place. Whereas multifunctional protein APE1 has been involved in base excision repair, redox regulation, and RNA processing, it remains unclear how APE1 plays critical functions in nucleolar ATR signaling and how APE1 recognizes and senses ssDNA gaps for the activation of ATR signaling. Our substantial preliminary data suggest that APE1 assembles into distinct liquid-liquid phase separation (LLPS) in vitro and in the nucleoli of cultured cancer cells but not normal cells to promote the ATR-Chk1 signaling, leading to compromised ribosomal RNA transcription and reduced cell viability. Furthermore, APE1 plays a direct role in the recognition and association of ssDNA gaps to recruit the ATR/ATRIP complex in in vitro reconstitution system and to promote the ATR checkpoint signaling in Xenopus egg extracts. Our central hypothesis in this project is that APE1 forms LLPS in vitro and in the nucleoli to promote the ATR checkpoint signaling and that APE1 directly recognizes ssDNA gaps for the recruitment and activation of ATR/ATRIP complex. We will elucidate the distinct regulatory mechanisms of APE1 in ATR signaling via two Specific Aims: (1) to determine the mechanisms of how APE1 forms liquid-liquid phase separation in vitro and in nucleoli to sense pH in cancer cells but not normal cells and promotes the nucleolar ATR-Chk1 checkpoint signaling to regulate rDNA transcription and sensitivity to chemotherapy drugs, and (2) to determine how APE1 directly associates with ssDNA gaps to promote the global ATR-Chk1 signaling in oxidative stress and DNA replication stress in Xenopus egg extracts and mammalian cells. We will test our major hypothesis regarding distinct mechanisms of APE1 in ATR DDR signaling using cutting-edge molecular biology, cell biology, and biochemical approaches in in vitro reconstitution systems with purified proteins, Xenopus egg extracts, and cultured mammalian cells. Anticipated results from this project will make a paradigm shift on how APE1 regulates ATR checkpoint signaling in the nucleoli and how APE1 recognizes and senses ssDNA gaps for the activation of the global ATR-Chk1 signaling to maintain genome stability. This work will provide novel insights into new strategies for cancer therapy such as modulating the distinct regulatory mechanisms of APE1 in ATR signaling in cancer cells.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $342,277 )
2026	2026	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Cancer Cause and Prevention Research	000	2	2/25/2026	NON-COMPETING CONTINUATION	$342,277
														Subtotal = $342,277

Issue Date FY: 2025 ( Subtotal = $342,569 )
2025	2025	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Cancer Cause and Prevention Research	000	1	2/3/2025	NEW	$342,569
														Subtotal = $342,569

Grand Total All Awards = $684,846

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Roles and regulations of APE1 in ATR signaling

Award Number: R01CA291546

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2025

PERIOD OF PERFORMANCE END DATE: 02/28/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer